Home › Kanser sa Bato (Renal Cell Carcinoma) › Rhode Island
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Rhode Island
6 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Rhode Island.
Mga Lungsod sa Rhode Island
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Rhode Island Hospital, East Providence
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06750185Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Lifespan Cancer Institute, Providence
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT03972657Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705, Providence
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT04777994A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Brown University Health Cancer Institute, Providence
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06362369Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.